TerminatedPhase 1NCT04088188
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Academic and Community Cancer Research United
- Principal Investigator
- Shubham PantAcademic and Community Cancer Research United
- Intervention
- Cisplatin(drug)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (7)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Spartanburg Regional Medical Center, Forest City, North Carolina, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04088188 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham